In our preliminary study, we have observed that PD could decrease the level of EGFR, an all-important upstream RTK of AKT pathway and an attractive target for NSCLC therapy, indicating a potential inhibiton of negative feedback by AKT inhibitors. Here, AKT1 is linked to non-small cell lung carcinoma.